Holen Sie sich die Stockscreener-App
94.07
0.08%
-0.0793
Schlusskurs vom Vortag:
$94.15
Offen:
$94.36
24-Stunden-Volumen:
5.07M
Relative Volume:
3.49
Marktkapitalisierung:
$7.12B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-23.82
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
+37.83%
1M Leistung:
+42.88%
6M Leistung:
+137.55%
1J Leistung:
+87.76%
1-Tages-Spanne:
$94.00
$94.36
1-Wochen-Bereich:
$66.13
$94.56
52-Wochen-Spanne:
$33.19
$94.56
Merus N V Stock (MRUS) Company Profile
Firmenname
Merus N V
Sektor
Branche
Telefon
31 030 253 8800
Adresse
YALELAAN 62, 3584 CM UTRECHT
Vergleichen Sie MRUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
94.09 | 7.14B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.95 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.01 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.28 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
772.72 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.17 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-08-25 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-07 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-21 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-03-28 | Eingeleitet | Truist | Buy |
| 2024-03-04 | Bestätigt | Needham | Buy |
| 2023-11-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-08-21 | Eingeleitet | TD Cowen | Outperform |
| 2022-08-02 | Eingeleitet | Stifel | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Needham | Buy |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-08 | Eingeleitet | William Blair | Outperform |
| 2021-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Buy |
| 2019-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Fortgesetzt | Guggenheim | Buy |
| 2019-04-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-03-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-12-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2016-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-06-13 | Eingeleitet | Citigroup | Buy |
| 2016-06-13 | Eingeleitet | Guggenheim | Buy |
| 2016-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Merus N V Aktie (MRUS) Neueste Nachrichten
Merus NV Hits Day High with 36.67% Surge in Intraday Performance - Markets Mojo
Foley Hoag Provides IP Due Diligence Counsel to Genmab A/S on Acquisition of Merus N.V. - Foley Hoag
Will Merus N.V. stock see PE expansionMarket Movers & Proven Capital Preservation Methods - newser.com
Will Merus N.V. see short term momentum2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
Relative strength of Merus N.V. in sector analysisJuly 2025 Short Interest & Risk Controlled Swing Alerts - newser.com
Genmab to acquire Merus for $8 billion in cash deal By Investing.com - Investing.com Nigeria
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V.MRUS - The AI Journal
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS) - PR Newswire
14 Best Biotech Stocks to Buy Right Now - Insider Monkey
Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium - Insider Monkey
Latham & Watkins Advises Merus in US$8 Billion Acquisition by Genmab - Latham & Watkins LLP
Genmab Nears Deal to Buy Cancer Drugmaker Merus - MSN
This Maplebear Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
MRUS Analyst Rating Update: Guggenheim Downgrades to Neutral | M - GuruFocus
MRUS Analyst Rating Update: Canaccord Genuity Adjusts PT and Rat - GuruFocus
Merus (MRUS) Sees Rating Downgrade and Target Price Raise by Wells Fargo | MRUS Stock News - GuruFocus
Merus (MRUS) Receives Rating Downgrade by LifeSci Capital | MRUS Stock News - GuruFocus
Barclays Downgrades MRUS, Lowers Price Target Amid Market Adjustments | MRUS Stock News - GuruFocus
Merus (MRUS) Sees Downgrade from UBS with Raised Price Target | MRUS Stock News - GuruFocus
Barclays Downgrades MRUS, Lowers Price Target Amid Market Adjust - GuruFocus
Merus (NASDAQ:MRUS) Receives "Market Perform" Rating from Lifesci Capital - MarketBeat
Barclays Downgrades Merus to Equalweight From Overweight, Adjusts Price Target to $97 From $112 - MarketScreener
BMO Capital Downgrades Merus to Market Perform From Outperform, Adjusts Price Target to $97 From $110 - MarketScreener
Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal - Stocktwits
Merus (NASDAQ:MRUS) Rating Lowered to "Hold" at Wells Fargo & Company - MarketBeat
Genmab Bets Big On Cancer With $8 Billion Merus Deal - Finimize
Merus Reaches Analyst Target Price - Nasdaq
How big funds are accumulating Merus N.V. (2GH) stock2025 Sector Review & Proven Capital Preservation Methods - newser.com
MRUS Stock Downgraded: HC Wainwright & Co. Lowers Price Target | - GuruFocus
Genmab to acquire Merus shares for $8bn - Yahoo Finance
Barclays downgrades Merus stock to Equalweight, cuts price target on valuation - Investing.com
Guggenheim downgrades Merus stock to Neutral following Genmab acquisition - Investing.com
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - AD HOC NEWS
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction - Yahoo Finance
EQT Is Shareholder in Merus, Acquired by Denmark's Genmab - MarketScreener
Merus stock rating downgraded by UBS after Genmab acquisition - Investing.com India
What’s the recovery path for long term holders of Merus N.V.Market Volume Report & Smart Money Movement Alerts - newser.com
Is Merus N.V. building a consolidation base2025 Winners & Losers & High Win Rate Trade Tips - newser.com
Genmab to acquire Merus for $8 billion in cash deal - Investing.com
Merus NV stock hits all-time high at 94.5 USD By Investing.com - Investing.com Australia
What margin trends mean for Merus N.V. stockWeekly Trend Report & High Conviction Buy Zone Picks - newser.com
Genmab swallows Merus in US$8bn deal - European Biotechnology Magazine
Genmab adding late-stage bispecific in $8B Merus acquisition - BioWorld MedTech
Mid Cap Stocks To ConsiderSeptember 29th - MarketBeat
Merus N.V. Stock: Analyzing Recent Fluctuations - timothysykes.com
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes - FinancialContent
Leadership Changes and Bold Moves Shake Global Drugmakers - Devdiscourse
Merus (MRUS) Experiences Surge with Significant Stock Price Incr - GuruFocus
Genmab’s $8B Merus takeout is latest push toward full ownership of programs - biocentury.com
Can Merus Sustain The Leap? - StocksToTrade
Transcript : Genmab A/S, Merus N.V.M&A Call - MarketScreener
Finanzdaten der Merus N V-Aktie (MRUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):